Revolutionary biodegradable pellet targets glue ear infection

July 21, 2011 in Diseases, Conditions, Syndromes

A revolutionary biodegradable pellet which slowly releases antibiotics into the middle ear could transform the lives of thousands of children who suffer from glue ear.

Scientists at The University of Nottingham have developed the tiny controlled-release antibiotic pellet which can be implanted in the during surgery to fit grommets, or small ventilation tubes. Over a period of three weeks it will release effective quantities of antibiotics to target any infection which can, in up to 20 per cent of cases, result in having to return for a second and sometimes a third operation.

The team has been led by John Birchall, Professor of Otorhinolaryngology, and Roger Bayston, Associate Professor of Surgical Infection, in the Faculty of Medicine and Health Sciences. Professor Birchall said: “Glue ear is one of the commonest complaints that we see in children in the ENT clinic. The condition causes hearing loss, problems with speech or schooling, and often it is accompanied by repeated ear infections. We are particularly concerned about children that have glue ear that comes back despite grommet surgery — with risks of permanent damage to the ear drum or the middle ear. This exciting new research to try to reduce the need for repeated grommet insertion involves ENT surgeons, microbiologists and pharmacists. Having such a multidisciplinary team on board means that we can take advantage of all the expertise available to help these children.”

Up to 80 per cent of children are affected temporarily by glue ear. Glue ear causes hearing impairment and subsequently can affect speech and schooling. Glue ear can also be associated with frequent ear infections. As many as 33,000 grommets are fitted in England and Wales every year. In Nottingham alone 300 to 400 children are referred to a specialist — 100 of them will require grommets. Whilst treatment with grommets is effective, the grommets are designed to extrude after about nine months or so. Unfortunately glue ear can return and one in five children will have to have surgery again.

Glue ear happens when a thick mucus collects inside the ear, at the other side of the ear drum. This interferes with hearing and therefore with schooling, social development and relationships with friends and siblings. Following research by this group and others, it is now recognised that glue ear is caused by biofilms — bacteria which grow together in a protective ‘slime’. They are very difficult to treat because they are capable of turning off target sites for common antibiotics, becoming up to 1,000 times less susceptible. In a significant proportion of cases, antibiotics have only a temporary effect and repeated grommet operations are needed.

First, the team produced a biodegradable pellet capable of doing the job. Dr Mat Daniel said: “We tested antibiotics against biofilms in the laboratory but it rapidly became apparent that very much higher levels of antibiotics would be needed. Because of that we knew that giving antibiotics by mouth was not going to work. We developed this biodegradable antibiotic pellet so we could put it directly into the ear — where the actual infection is. We hope that in the future this may very much reduce the need for any children to have more than one operation.”

Next, they found a way of demolishing the biofilm to make the infection easier to treat. This work has been the responsibility of Dr Saif Al-Zahid. He said: “Bacteria in biofilms are held together in a strong matrix. We have recently found that the expectorant N-Acetylcysteine is able to break down this biofilm matrix effectively — thereby releasing bacteria to a free-floating planktonic form. In doing so become much more effective in killing bacteria as the protective properties of a biofilm are no longer present. N-Acetylcysteine has an added benefit due to its mucus reducing properties — this is desirable in glue ear as the middle ear is filled with a thick mucus secretion. As a result the addition of N-Acetylcysteine in our antibiotic pellet would be likely to increase the chance of eradicating middle ear biofilms and speed up the resolution of glue ear.”

Provided by University of Nottingham search and more info website

not rated yet  

Rank not rated yet
Relevant PhysicsForums posts

More news stories

FDA warns of infections tied to Tennessee pharmacy

(AP)—Government health officials are investigating several health problems reported with potentially contaminated medications made by a Tennessee specialty pharmacy.

Diseases, Conditions, Syndromes created May 24, 2013 | popularity not rated yet | comments 0

Comorbidities common with alopecia areata

(HealthDay)—Comorbid conditions often accompany alopecia areata, according to a study published online May 22 in JAMA Dermatology.

Diseases, Conditions, Syndromes created May 24, 2013 | popularity not rated yet | comments 0

Top-ranked golfer beats scoliosis

(HealthDay)—As a world-class golfer, Stacy Lewis' accomplishments are remarkable. But it was a physical challenge in her childhood that defined her ascent to the top of her sport.

Diseases, Conditions, Syndromes created May 24, 2013 | popularity not rated yet | comments 0

Saudi to send animal samples to US in coronavirus probe (Update)

Saudi Arabia said Friday it would send samples taken from animals possibly infected with a deadly SARS-like virus to the United States for testing in a bid to find the source of disease.

Diseases, Conditions, Syndromes created May 24, 2013 | popularity not rated yet | comments 0

WHO voices deep concern over spread of SARS-like virus

The World Health Organization voiced deep concern Thursday over the SARS-like virus that has killed 22 people in less than a year, saying it might potentially spread more widely between humans.

Diseases, Conditions, Syndromes created May 24, 2013 | popularity 5 / 5 (1) | comments 0


First drug to improve heart failure mortality in over a decade

Coenzyme Q10 decreases all cause mortality by half, according to the results of a multicentre randomised double blind trial presented today at Heart Failure 2013 congress. It is the first drug to improve heart failure mortality ...

Seniors more likely to crash when driving with pet, study finds

(HealthDay)—Animals make great companions for senior citizens, but elderly people who always drive with a pet in the car are far more likely to crash than those who never drive with a pet, researchers have ...

Heart failure accelerates male 'menopause'

Heart failure accelerates the aging process and brings on early andropausal syndrome (AS), according to research presented today at the Heart Failure Congress 2013. AS, also referred to as male 'menopause', was four times ...

Death highest in heart failure patients admitted in January, on Friday, and overnight

Mortality and length of stay are highest in heart failure patients admitted in January, on Friday, and overnight, according to research presented today at the Heart Failure Congress 2013. The analysis of nearly 1 million ...

Feds fight morning-after pill age ruling in NY

(AP)—Department of Justice lawyers have again asked a federal appeals court in New York to delay lifting age restrictions and prescription requirements on an emergency contraceptive popularly known as the morning-after ...

New immune system discovered

(Medical Xpress)—A research team, led by Jeremy Barr, a biology post-doctoral fellow, unveils a new immune system that protects humans and animals from infection.